EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017.
“We are thrilled that GOCOVRI (amantadine) extended release capsules is approved for Parkinson’s disease patients with dyskinesia receiving levodopa-based therapy and now available for physician and patient use,” stated Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “This is a momentous milestone for Adamas, as significantly improving patient lives with our approved medicines is the primary driver of our time-dependent biology approach to science, discovery and clinical development.”
- Received approval by the U.S. Food and Drug Administration (FDA) for GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, on August 24, 2017. GOCOVRI is the first and only medicine approved by the FDA for this indication.
- Earned seven-years of orphan drug exclusivity from the FDA for GOCOVRI, which will continue through August 24, 2024.
- Provided access to GOCOVRI for physicians and patients through its distribution network and GOCOVRI Onboard, Adamas’ patient services support program.
- Hired six regional sales leaders to manage its planned 59 neurology account specialist sales force.
- Published GOCOVRI (ADS-5102) Phase 3 EASE LID 2 open-label clinical trial data in the Journal of Parkinson’s Disease. The data demonstrated tolerability and durability out to 88 weeks and a subgroup analysis showed that patients previously having undergone Deep Brain Stimulation also received benefit from ADS-5102.
- Published GOCOVRI (ADS-5102) Phase 3 EASE LID 3 clinical trial data in Movement Disorders. The data demonstrated that ADS-5102 significantly reduced both dyskinesia and OFF time at three months in Parkinson’s disease patients with dyskinesia on levodopa-based therapy and confirmed the results from the EASE LID study, as published in JAMA Neurology, which showed the significant reduction in dyskinesia and OFF time for 6 months.
- Completed ADS-4101 (lacosamide) modified release capsules Phase 1b steady-state pharmacokinetic study. ADS-4101 is in development for the treatment of partial onset seizures in patients with epilepsy. The study demonstrated that a 600 mg dose of ADS-4101, taken once-nightly, provided a 1.5-2.5 fold increase in average lacosamide concentrations throughout the day compared to the maximum approved daily dose of 400 mg, taken as 200 mg twice-daily, of VIMPAT® (lacosamide) immediate release tablets in healthy volunteers, with comparable tolerability. These Phase 1 data are scheduled to be presented at the American Epilepsy Society Annual Meeting in December 2017.
- Appointed Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to the Adamas Board of Directors.
Third Quarter 2017 Financial Results
Adamas reported a net loss of $23.4 million, or $1.04 per share, basic and diluted, for the third quarter of 2017, compared to a net loss of $14.4 million, or $0.66 per share, basic and diluted, for the third quarter of 2016. The net losses for the third quarters of 2017 and 2016 included $3.3 million and $2.6 million, respectively, in non-cash stock-based compensation expense.
Research and development expenses were $6.5 million for the third quarter of 2017, including $0.8 million in stock-based compensation expense, compared to $7.4 million for the comparable quarter of 2016, including $0.7 million in stock-based compensation expense. In the third quarter of 2016, Adamas was focused on pre-commercial manufacturing activities and the completion of the Phase 3 clinical program for now approved GOCOVRI. In the third quarter of 2017, research and development activities were primarily the ongoing open-label safety study for GOCOVRI, building of pre-FDA approval inventory, and development work for ADS-4101 and ADS-5102 (GOCOVRI) for the treatment of walking impairment in patients with multiple sclerosis.
Selling, general and administrative expenses for the third quarter ended September 30, 2017, were $16.1 million, including $2.4 million in stock-based compensation expense, compared to $7.3 million for the quarter ended September 30, 2016, which included $1.9 million in stock-based compensation expense. The increase in selling, general and administrative expenses was primarily due to growth in commercial and administrative expenses in preparation for the commercial launch of GOCOVRI.
Nine-month 2017 Financial Results
Adamas reported a net loss for the nine months ended September 30, 2017, of $60.1 million, or $2.69 per share, basic and diluted, compared with a net loss for the same period in 2016 of $45.1 million, or $2.09 per share, basic and diluted. Research and development expenses for the nine months ended September 30, 2017, were $20.7 million, including $2.6 million in stock-based compensation expense, compared to $24.2 million for the nine months ended September 30, 2016, which included $2.1 million in stock-based compensation expense. Selling, general and administrative expenses for the nine months ended September 30, 2017, were $38.3 million, including $7.4 million in stock-based compensation expense, compared to $22.0 million for the nine months ended September 30, 2016, which included $5.6 million in stock-based compensation expense.
Adamas ended the quarter with $130.7 million of cash, cash equivalents, and available-for-sale securities, compared to $135.9 million at December 31, 2016. The company expects to receive $65 million in funding from HealthCare Royalty Partners (HCRP) in the fourth quarter of 2017, as part of the $100 million royalty-backed note the company signed in May 2017.
“With the $65 million proceeds from HCRP, together with our current available cash, cash equivalents and investments of $130.7 million as of September 30, 2017, we believe we will be sufficiently capitalized to launch and commercialize GOCOVRI, complete the Phase 3 studies of ADS-5102 in multiple sclerosis patients with walking impairment and initiate a Phase 3 study of ADS-4101 in epilepsy patients with partial onset seizures,” stated Alfred G. Merriweather, Chief Financial Officer of Adamas Pharmaceuticals, Inc.
Investor Conference Call and Webcast
Adamas will host a conference call and webcast today, November 2, 2017, at 4:30 p.m. Eastern Time. The conference call may be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until December 2, 2017.
GOCOVRI (amantadine) extended release capsules is the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is a high-dose 274 mg amantadine taken once-daily at bedtime, which delivers consistently high levels of amantadine in the morning and throughout the day when dyskinesia is most prevalent.
For more information about GOCOVRI, including important safety information and full U.S. Prescribing Information, please call 1-844-GOCOVRI [1-844-462-6874] or visit www.GOCOVRI.com.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson’s disease; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information, please visit www.adamaspharma.com.
VIMPAT® is a trademark of UCB.
Statements contained in this press release regarding matters that relate to future events, conditions, or circumstances are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas’ expectation of receiving $65 million in funding from HealthCare Royalty Partners in the fourth quarter of 2017, and its belief with respect to the sufficiency of its financial resources in Mr. Merriweather’s quote. Words such as “expects,” “believe” and other words or expressions referencing future events, conditions, or circumstances are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development, and commercial activities relating to GOCOVRI, ADS-5102 and ADS-4101, the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2017, particularly under the caption “Risk Factors.” Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.
— Financial Tables Attached —
|Adamas Pharmaceuticals, Inc.|
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended|
|Nine Months Ended|
|License and grant revenue||$||1||$||138||$||3||$||535|
|Research and development||6,459||7,437||20,723||24,183|
|Selling, general and administrative, net||16,064||7,344||38,323||22,043|
|Total operating expenses||22,523||14,781||59,046||46,226|
|Loss from operations||(22,522||)||(14,643||)||(59,043||)||(45,691||)|
|Interest and other income, net||839||249||1,265||593|
|Loss before income taxes||(23,360||)||(14,394||)||(60,184||)||(45,098||)|
|Benefit for income taxes||—||—||(51||)||—|
|Net loss per share, basic and diluted||$||(1.04||)||$||(0.66||)||$||(2.69||)||$||(2.09||)|
|Weighted average shares used in computing net loss per share, basic and diluted||22,569||21,941||22,390||21,616|
|Adamas Pharmaceuticals, Inc.|
Unaudited Consolidated Balance Sheet Data
|Cash, cash equivalents, and available-for-sale securities||$||130,730||$||135,944|
|Total current liabilities||15,211||9,743|
|Total stockholders’ equity||85,878||132,183|
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 email@example.com
Source:Adamas Pharmaceuticals, Inc.